CRA advanced analytics was hired by a pharmaceutical company to assess the impact of Covid-19 on the forecast of their pulmonology product in the US. Using the client’s geographical-level internal sales data, combined with publicly available coronavirus metrics, we were able estimate the trend to their product demand, segmented by state-level Covid-19 severity. The team’s findings were presented to the company’s leadership and board of investors, where the analysis was praised for its technical merit and sophistication in providing data-driven guidance surrounding the level of potential risk to their business.
Psoriasis patient source of business for major IL-23 agents
CRA analytics insight A higher proportion of Tremfya patients, versus Skyrizi patients, were previously treated with an IL-17 agent (i.e., Cosentyx or Taltz)...